Literature DB >> 28421779

Oral glutamine reduces myocardial damage after coronary revascularization under cardiopulmonary bypass. A randomized clinical trial.

Mariana Chávez-Tostado1, Fernando Carrillo-Llamas, Porfirio Eduardo Martínez-Gutiérrez, Araceli Alvarado-Ramírez, Jaime Gilberto López-Taylor, José Clemente Vásquez-Jiménez, Clotilde Fuentes-Orozco, Jorge Rendón-Félix, Leire Irusteta-Jiménez, Vanessa Carolina Calil-Romero, José Antonio Ramírez-Jiménez, Luis Rodrigo Michel-Espinoza, Carmen Karina Contreras-López, Lizbeth Araceli Cuesta-Márquez, Alejandro González-Ojeda.   

Abstract

BACKGROUND: Glutamine is the most abundant free amino acid in the body. It modulates immune cell function and is an important energy substrate for cells in critically ill patients. Reduction of injury cardiac markers had been observed in patients receiving intravenous glutamine and in a pilot study with oral glutamine. The aim of this study was to analyze the effect of preoperative oral supplementation of glutamine on postoperative serum levels of cardiac injury markers.
METHODS: A randomized clinical trial was performed in 28 Mexican patients with ischemic heart disease who underwent cardiopulmonary bypass with extracorporeal circulation. Patients were randomly assigned to receive oral glutamine (0.5 g/kg/day) or maltodextrin 3 days before surgery. Cardiac injury markers as troponin-I, creatine phosphokinase, and creatine phosphokinase-Mb were measured at 1, 12, and 24 hours postoperatively.
RESULTS: At 12 and 24 hours serum markers levels were significantly lower in the glutamine group compared with controls (p = 0.01 and p = 0.001, respectively) (p = 0.004 and p < 0.001, respectively). Overall, complications were significantly lower in the glutamine group (p = 0.01, RR = 0.54, 95% CI 0.31-0.93). Mortality was observed with 2 cases of multiple organ failure in control group and 1 case of pulmonary embolism in glutamine group (p = 0.50).
CONCLUSION: Preoperative oral glutamine standardized at a dose of 0.5 g/kg/day in our study group showed a significant reduction in postoperative myocardial damage. Lower cardiac injury markers levels, morbidity and mortality were observed in patients receiving glutamine.

Entities:  

Keywords:  Glutamine. Cardiac surgery. Cardiopulmonary bypass. Troponin-I. CPK. CPK-Mb.

Mesh:

Substances:

Year:  2017        PMID: 28421779     DOI: 10.20960/nh.519

Source DB:  PubMed          Journal:  Nutr Hosp        ISSN: 0212-1611            Impact factor:   1.057


  5 in total

1.  Metabolic Intersection of Cancer and Cardiovascular Diseases: Opportunities for Cancer Therapy.

Authors:  Giang Hoang; Kiet Nguyen; Anne Le
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Protein O-GlcNAcylation in Cardiac Pathologies: Past, Present, Future.

Authors:  Marine Ferron; Manon Denis; Antoine Persello; Raahulan Rathagirishnan; Benjamin Lauzier
Journal:  Front Endocrinol (Lausanne)       Date:  2019-01-15       Impact factor: 5.555

Review 3.  The Emerging Role of l-Glutamine in Cardiovascular Health and Disease.

Authors:  William Durante
Journal:  Nutrients       Date:  2019-09-04       Impact factor: 5.717

Review 4.  Glutamine Metabolism Is Essential for Stemness of Bone Marrow Mesenchymal Stem Cells and Bone Homeostasis.

Authors:  Tao Zhou; Yuqing Yang; Qianming Chen; Liang Xie
Journal:  Stem Cells Int       Date:  2019-09-12       Impact factor: 5.443

5.  The effects of preoperative supplementation with a combination of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine on inflammatory and hematological markers of patients with heart surgery: a randomized controlled trial.

Authors:  Mona Norouzi; Azadeh Nadjarzadeh; Majid Maleki; Sayyed Saeid Khayyatzadeh; Saeid Hosseini; Mehdi Yaseri; Hamed Fattahi
Journal:  BMC Surg       Date:  2022-02-11       Impact factor: 2.102

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.